HomeAI · summaries
Storia in 3 fonti
Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes
NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented at the American Diabetes Association Scientific Sessions.Acmopatide (Roche), formerly known as CT-868, delivered a wide range of benefits among people with type 1 diabetes. Beyond improvements in HbA1c and body
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
- ·
endpoints.news
Roche’s incretin shot works in mid-stage trial in type 1 diabetes
Roche's acmopatide cut A1C by 0.34% and reduced insulin use by 15% in a Phase 2 trial in type 1 diabetes patients with obesity.
- ·
healio.com
Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes
NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented…
- ·
Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
- ·
Berobenatide shows promise for monthly GLP-1 dosing
NEW ORLEANS — New data from three phase 2b studies demonstrate substantial weight loss with berobenatide, an ultralong-acting GLP-1 receptor agonist, in people with obesity or…
- ·
Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results
Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results